A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT ID: NCT06131437
Last Updated: 2026-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
809 participants
INTERVENTIONAL
2023-11-27
2026-01-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
NCT06388187
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
NCT06716307
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CagriSema 2.4 mg/2.4 mg
Participants will receive 2.4 mg cagrilintide and 2.4 mg semaglutide subcutaneously once-weekly (dose escalation period of 16 weeks) for up to 84 weeks.
Cagrilintide
Cagrilintide will be administered subcutaneously.
Semaglutide
Semaglutide will be administered subcutaneously.
Tirzepatide 15 mg
Participants will receive 15 mg tirzepatide subcutaneously once-weekly (dose escalation period of 20 weeks) for up to 84 weeks.
Tirzepatide
Tirzepatide will be administered subcutaneously.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cagrilintide
Cagrilintide will be administered subcutaneously.
Semaglutide
Semaglutide will be administered subcutaneously.
Tirzepatide
Tirzepatide will be administered subcutaneously.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years or above at the time of signing the informed consent
* Body mass index (BMI) of ≥ 30.0 kilogram per square meter (kg/m\^2)
Exclusion Criteria
* History of type 1 or type 2 diabetes mellitus
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Transparency (dept. 2834)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univ of Alabama Birmingham
Birmingham, Alabama, United States
Chambliss Clinical Trials LLC
Montgomery, Alabama, United States
FDRC
Costa Mesa, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Univ of Colorado at Denver
Aurora, Colorado, United States
Yale University School Of Medicine
New Haven, Connecticut, United States
Northeast Research Institute
Fleming Island, Florida, United States
Jacksonville Ctr For Clin Res
Jacksonville, Florida, United States
South Broward Research LLC
Miramar, Florida, United States
Hope Clin Res & Wellness
Conyers, Georgia, United States
East West Med Res Inst
Honolulu, Hawaii, United States
Great Lakes Clinical Trials
Chicago, Illinois, United States
Endeavor Health
Skokie, Illinois, United States
Evanston Premier Hlthcr Res
Skokie, Illinois, United States
Midwest Inst For Clin Res
Indianapolis, Indiana, United States
Northern Pines Hlth Ctr, PC
Buckley, Michigan, United States
StudyMetrix Research LLC
City of Saint Peters, Missouri, United States
Comprehensive Weight Ctrl Prog
New York, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Medication Mgmnt, LLC_Grnsboro
Greensboro, North Carolina, United States
PharmQuest Life Sciences LLC
Greensboro, North Carolina, United States
Accellacare_NC
Raleigh, North Carolina, United States
Accellacare
Wilmington, North Carolina, United States
New Venture Medical Research
Wadsworth, Ohio, United States
Lynn Institute of Norman
Norman, Oklahoma, United States
The University of Penn Center
Philadelphia, Pennsylvania, United States
Clinical Res Collaborative
Cumberland, Rhode Island, United States
Medical University Of South Carolina
Charleston, South Carolina, United States
Coastal Carolina Res Ctr
North Charleston, South Carolina, United States
Hillcrest Clinical Research
Simpsonville, South Carolina, United States
Spartanburg Medical Research
Spartanburg, South Carolina, United States
Holston Medical Group_Bristol
Bristol, Tennessee, United States
Holston Medical Group
Kingsport, Tennessee, United States
Amarillo Med Spec LLP
Amarillo, Texas, United States
Elligo Clin Res Centre
Austin, Texas, United States
UT Health University of Texas
Bellaire, Texas, United States
Baylr Sctt White Rs Inst, Endo
Dallas, Texas, United States
Velocity Clin Res, Dallas
Dallas, Texas, United States
UT Southwestern Medical Center-CRU
Dallas, Texas, United States
DCOL Ctr for Clin Res
Longview, Texas, United States
Washington Cntr Weight Mgmt
Arlington, Virginia, United States
Health Res of Hampton Roads
Newport News, Virginia, United States
National Clin Res Inc.
Richmond, Virginia, United States
Selma Medical Associates
Winchester, Virginia, United States
Capital Clin Res Ctr,LLC
Olympia, Washington, United States
Rainier Clin Res Ctr Inc
Renton, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1292-4835
Identifier Type: OTHER
Identifier Source: secondary_id
NN9838-7832
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.